used to treat hypoactive sexual desire disorder in premenopausal women
Bremelanotide
Structural features
SMILES
CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O
Sequence
Ac-XDHfRWK
Route of administration
SC
Terminal half-life
2.7 hours
Protein binding
0.21
Absorption and Bioavailability
1